Novartis makes its case on why RTH258 can grab a blockbuster piece of Regeneron's AMD market
Soon-to-be Novartis $NVS CEO Vas Narasimhan has peeled back the cover on more detailed Phase III data for their blockbuster Eylea rival RTH258 (brolucizumab), explaining why he believes the pharma giant has a new drug for wet age-related macular degeneration that has proven to be considerably better than Regeneron’s $5 billion franchise therapy Eylea. But he has one other hurdle to clear before making a slightly paused arrival at the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.